Connect with us

Press Release

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Published

3 hours ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.

 

The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.

 

The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.

 

More information about Monofer®

Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.

 

More information about Cosmofer®

Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.

 

About Iron Deficiency and Iron Deficiency Anemia

ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.

 

About Pharmacosmos A/S

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

  1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
  2. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
  3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
  5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
  6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Bry-Air to Showcase Revolutionary 60 Percent Energy-Saving MOF Dehumidification Technology at India Pharma Expo 2026

Published

2 hours ago

on

April 27, 2026

By

India, 27th Apr 2026 – As the global pharmaceutical industry gathers for the India Pharma Expo 2026 at the HITEX Exhibition Centre in Hyderabad from April 23 to 25, Bry-Air Pvt Ltd, a global pioneer in environmental control solutions, is set to demonstrate its next-generation technologies designed specifically to meet the rigorous compliance and sustainability demands of Pharma 4.0 manufacturing. Moving beyond generic air quality management, Bry-Air is reinforcing its leadership in India by introducing a paradigm shift in pharmaceutical humidity control. 

From Silica to MOF: Redefining Pharmaceutical Humidity Control For 35 years, the pharmaceutical industry has relied heavily on silica gel as a desiccant for dehumidification. At the India Pharma Expo, Bry-Air is unveiling a breakthrough dehumidifier utilizing Metal-Organic Frameworks (MOFs); a highly porous material technology linked to Nobel Prize-winning chemistry. This MOF-integrated technology delivers a staggering 60% reduction in energy consumption compared to traditional systems while maintaining strict atmospheric sterility. Achieving rotor regeneration temperatures as low as 80°C, this innovation is specifically tailored to prevent contamination in dry powder filling, soft gelatin capsule manufacturing, and vial filling, solving critical operational and environmental challenges for modern pharmaceutical factories. 

Securing the Pharma Cold Chain with Comprehensive Dehumidification Solutions 

With cold chain logistics serving as a major theme at the expo, Bry-Air addresses the challenges of vaccine and biological refrigeration environments with its advanced cold room dehumidifiers. From cold storage dehumidifiers to desiccant dehumidifiers for cold rooms, Bry-Air provides solutions that prevent condensation, ice formation, and moisture-related damage in temperature-sensitive storage facilities. These systems include freezer dehumidification, cold dehumidifiers, and dehumidifiers for cold rooms, enabling pharmaceutical logistics providers and food processing industries to maintain product efficacy and comply with strict regulatory standards. The company’s cold room dehumidification solutions exemplify Bry-Air’s commitment to performance and reliability in challenging environments. 

Sustainable Operations with Advanced Adsorption Chillers 

Bry-Air’s adsorption chillers remain at the forefront of sustainable cooling technology for large-scale pharmaceutical and chemical manufacturing. As leading adsorption chiller manufacturers, Bry-Air designs chillers that leverage desiccant-based adsorption principles to deliver efficient and eco-friendly cooling for industrial applications. These desiccant coolers are tailored to meet the decarbonization goals of modern manufacturing by converting low-grade industrial waste heat into operational cooling energy, offering reduced energy consumption while maintaining precise temperature control. 

Beyond Pharma: Enabling the EV Transition with Dry Room Solutions 

While showcasing its pharmaceutical prowess, Bry-Air continues to dominate other critical sectors. Meeting the exacting requirements of the lithium battery industry, Bry-Air offers state-of-the-art dry room solutions. Designed for battery dry rooms, dry rooms for battery manufacturing, and lithium battery dry rooms, these solutions provide a controlled, low-humidity environment essential for high-quality battery production. The dry rooms are equipped with specialized dry room dehumidifiers to maintain consistent air conditioning, ensuring the longevity, performance, and safety of sensitive battery materials. 

A Commitment to Engineering Excellence and “Make for the World” As the flagship company of the Pahwa Group, with over 60 years of expertise, Bry-Air embodies the organization’s dedication to engineering excellence and continuous innovation. Operating alongside Desiccant Rotors International (DRI), Delair, and Technical Drying Services (TDS), Bry-Air champions the “Make in India to Make for the World” philosophy, exporting solutions to over 40 countries globally. 

Industry professionals, facility managers, and media attending the India Pharma Expo 2026 are invited to visit the Bry-Air exhibition booth to experience these advanced dehumidification technologies firsthand. 

For more information about Bry-Air’s innovative products and services in India, visit https://www.bryair.com/ or contact the Pahwa Group at bryairmarketing@pahwa.com 

About Bry-Air Pvt Ltd 

Bry-Air Pvt Ltd is a leading provider of dehumidification and environmental control solutions with over six decades of experience. A part of the Pahwa Group, Bry-Air specializes in designing and manufacturing high-quality air management systems, including desiccant chillers, dry rooms, and cold storage dehumidifiers, serving industries across India and beyond. 

Media Contact

Organization: Bry-Air Pvt Ltd

Contact Person: Support team

Website: https://www.bryair.com/

Email: Send Email

Country:India

Release id:44425

The post Bry-Air to Showcase Revolutionary 60 Percent Energy-Saving MOF Dehumidification Technology at India Pharma Expo 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

10 Things Every Watch Collector Can Now Track for Free on WatchPolice.com

Published

2 hours ago

on

April 27, 2026

By

From grey market pricing to tariff guides to restock alerts, the new platform replaces a dozen browser tabs with one free dashboard

United States, 27th Apr 2026 — WatchPolice.com officially launched today as a free, all-in-one tracking platform for watch enthusiasts and microbrand collectors. Built to replace the patchwork of forums, Discord servers, Instagram alerts, and spreadsheets that collectors currently rely on, the platform consolidates ten essential tools into a single dashboard — at zero cost.

Here are the 10 things WatchPolice.com tracks for collectors, starting today:

1. New Release Alerts

Follow any brand or microbrand and get instantly notified the moment a new watch is announced. No more refreshing brand websites or scrolling Instagram at midnight.

2. Grey Market Pricing

See current asking prices and recent sold data across major secondary marketplaces in one view. Spot trends, identify deals, and avoid overpaying.

3. Back-in-Stock Notifications

Get an alert the second a sold-out reference becomes available again — whether it’s a hyped microbrand drop or a hard-to-find dial variant.

4. Price Drop and Price Increase Alerts

Set a target price on any tracked watch and get notified when it moves. Works for new retail listings and grey market changes alike.

5. Watches in the Press

A curated feed pulling in watch coverage from major publications, YouTube reviewers, and independent media — so collectors see what’s being talked about without hunting it down.

6. The Unified Drop Calendar

Hundreds of brands. One calendar. See exactly what’s launching, when, and from whom — including microbrand drops that rarely make the mainstream watch press.

7. The Community Board

A forum-style space for collectors to share finds, ask questions, post wrist shots, and weigh in on releases. Built for the people who actually wear the watches.

8. The Promo Code Database

A regularly updated, community-verified list of working discount codes for brands and retailers. No expired codes. No clickbait coupon sites.

9. The WatchPolice Tariff Guide

A plain-English, regularly updated breakdown of how import duties, tariffs, and taxes affect watch pricing across regions — so collectors know the real landed cost before they buy.

10. Side-by-Side Watch Comparison

Compare any two (or more) watches across specs, pricing, availability, and grey market performance. Useful for shortlisting a next purchase or settling a debate.

Built for Collectors, Free for Everyone

Every feature on WatchPolice.com is available at no cost. The platform is independent, community-driven, and built specifically for the people making and collecting watches today — including the rapidly growing microbrand scene that often gets overlooked by larger industry tools.

“Collectors shouldn’t have to monitor twenty browser tabs, three Discords, and a half-dozen Instagram accounts just to keep up with the watches they’re tracking,” said a representative for WatchPolice.com. “We built this so the information comes to you — instantly, in one place, and free.”

Availability

WatchPolice.com is live now at WatchPolice.com. Account creation is free and takes under a minute. The platform is mobile-optimized for iOS and Android browsers.

About WatchPolice.com

WatchPolice.com is a free tracking and intelligence platform for watch enthusiasts and microbrand collectors. The platform delivers real-time alerts on new releases, grey market pricing, restocks, and price movements, alongside community tools, drop calendars, promo codes, tariff guidance, and side-by-side comparisons. WatchPolice.com is independent and built by collectors, for collectors.

Media Contact

WatchPolice.com Press Email: press@watchpolice.com Web: WatchPolice.com

Media Contact

Organization: Watch Police

Contact Person: Steven

Website: https://watchpolice.com/

Email: Send Email

Country:United States

Release id:44424

The post 10 Things Every Watch Collector Can Now Track for Free on WatchPolice.com appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Thole Law Firm Highlights Decades of Legal Excellence and Community Leadership in Stillwater

Published

2 hours ago

on

April 27, 2026

By

Stillwater, Minnesota, United States, 27th Apr 2026 — The Thole Law Firm, led by seasoned defense attorney Eric Thole, continues to stand out as a trusted legal advocate for individuals facing criminal charges throughout Stillwater and the surrounding Washington County area. With a career rooted in both legal excellence and community service, Eric Thole has built a reputation for delivering strategic, results-driven defense for over two decades.

Before establishing his own practice in 2005, Eric Thole developed a strong legal foundation through years of public service and private practice. He spent the early part of his career working at law firms representing municipalities such as Stillwater and Cottage Grove. His legal expertise further expanded during his eight-year tenure as an assistant Washington County attorney, where he prosecuted felony cases and gained invaluable courtroom experience from the prosecution’s side.

Since founding the Thole Law Firm, Thole has defended more than 2,000 individuals, demonstrating a deep commitment to protecting the rights of his clients. His approach is rooted in the belief that one mistake—or even a false accusation—should not define a person’s future. This philosophy has become a cornerstone of his practice and continues to guide his work as a criminal defense attorney.

Those searching for eric thole attorney at law or eric thole will find a professional known not only for his legal knowledge but also for his personalized approach to each case. Thole emphasizes careful case analysis, strategic planning, and strong advocacy to ensure every client receives the best possible defense.

Beyond the courtroom, Eric Thole’s background reflects a strong tradition of leadership and discipline. He began his journey at North Dakota State University, where he played football and was part of the 1985 NCAA Division II National Championship team. He later transferred to Macalester College, contributing to the winningest football team in the school’s history while earning recognition as the top male scholar-athlete in his graduating class. These early accomplishments highlight the dedication and work ethic that continue to define his professional career.

Thole’s influence extends well beyond his legal practice. A respected member of the community, he has served as a Stillwater City Councilman and played a key role in supporting local youth programs. As a founding member of both the Stillwater Football and Basketball Booster Board of Directors, he has contributed to strengthening community engagement and youth development initiatives.

His leadership within the legal community is equally notable. Eric Thole previously served as President of the Washington County Bar Association, where he worked alongside fellow attorneys to promote legal excellence and uphold professional standards across the region.

At the Thole Law Firm, clients can expect more than just legal representation—they gain an advocate who is deeply invested in their future. Thole’s comprehensive understanding of both prosecution and defense allows him to anticipate challenges and craft effective strategies tailored to each unique situation.

Individuals seeking experienced criminal defense representation in Stillwater and nearby areas are encouraged to learn more about the firm’s services by visiting the official website at https://www.tholelaw.com/ .

About Thole Law Firm
The Thole Law Firm is a Stillwater-based legal practice focused on criminal defense. Founded by Eric Thole in 2005, the firm has successfully represented thousands of clients across Washington County. With a commitment to justice, integrity, and personalized advocacy, the firm continues to be a trusted resource for individuals navigating complex legal challenges.

Media Contact

Organization: Thole Law Firm

Contact Person: Eric Thole

Website: https://www.tholelaw.com/

Email: Send Email

Contact Number: +16513689407

City: Stillwater

State: Minnesota

Country:United States

Release id:44417

The post Thole Law Firm Highlights Decades of Legal Excellence and Community Leadership in Stillwater appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us